Inhibitory interneurons are crucial to brain function and their dysfunction is implicated in neuropsychiatric conditions. Emerging evidence indicates that cholecystokinin (CCK)-expressing interneurons (CCK+) are highly heterogenous. We find that a large subset of parvalbumin-expressing (PV+) interneurons express CCK strongly; between 40 and 56% of PV+ interneurons in mouse hippocampal CA1 express CCK. Primate interneurons also exhibit substantial PV/CCK co-expression. Mouse PV+/CCK+ and PV+/CCK- cells show distinguishable electrophysiological and molecular characteristics. Analysis of single nuclei RNA-seq and ATAC-seq data shows that PV+/CCK+ cells are a subset of PV+ cells, not of synuclein gamma positive (SNCG+) cells, and that they strongly express oxidative phosphorylation (OXPHOS) genes. We find that mitochondrial complex I and IV-associated OXPHOS gene expression is strongly correlated with CCK expression in PV+ interneurons at both the transcriptomic and protein levels. Both PV+ interneurons and dysregulation of OXPHOS processes are implicated in neuropsychiatric conditions, including autism spectrum (ASD) disorder and schizophrenia (SCZ). Analysis of human brain samples from patients with these conditions shows alterations in OXPHOS gene expression. Together these data reveal important molecular characteristics of PV-CCK co-expressing interneurons and support their implication in neuropsychiatric conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041731 | PMC |
http://dx.doi.org/10.1038/s41380-023-02153-5 | DOI Listing |
Alzheimers Dement
December 2024
GloNeuro Academy, Noida, Uttar Pradesh, India.
Background: Obesity and ageing individually pose significant challenges to global public health, leading to preventable deaths. With an increasing geriatric population due to improved medical interventions, the intersection of these health issues becomes a critical concern worldwide. Both developed and developing countries grapple with the consequences of obesity, a major risk factor for various conditions like cardiovascular diseases, hypertension, type 2 diabetes, dementia, and neuropsychiatric diseases.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute of Transformative Molecular Medicine, Case western Reserve University, Cleveland, OH, USA.
Background: Alzheimer's disease (AD) is a severe neurodegenerative condition that affects millions of people worldwide. The TgF344 AD rat model, which exhibits early depression-like behavior followed by later cognitive impairment, is widely used to evaluate putative biomarkers and potential treatments for AD. The P7C3 neuroprotective compounds have shown protective efficacy for both brain pathology and neuropsychiatric impairment in this model.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Georgia Institute of Technology, Atlanta, GA, USA.
Background: Chronic stress promotes life-long risk for neuropsychiatric decline by increasing neuroinflammation and disrupting synaptic health and plasticity. Our lab and others have recently demonstrated that non-invasive gamma sensory stimulation (flicker) modulates immune signaling, restores microglial function, and improves cognitive performance in mouse models of Alzheimer's disease (AD). However, no research to date has studied the effects of flicker in the context of stress.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, ON, Canada.
Background: The endocannabinoid system has demonstrated roles in Alzheimer's Disease (AD), such as modulation of inflammation. Fatty Acid Amide Hydrolase (FAAH) is the enzyme responsible for the rapid inactivation of the endocannabinoid anandamide into arachidonic acid and ethanolamine. In doing so, FAAH modulates the concentration of anandamide and influences neurobehavioral functions and physiological conditions such as nociception and inflammatory responses.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
School of Medicine of Ribeirão Preto, University of São Paulo, RIBEIRAO PRETO, Brazil.
Background: Families with a history of Alzheimer's Disease (AD) may have a genetic predisposition that raises the risk of developing the condition. However, not all members of these families can undergo genetic testing. Thus, this study aims to evaluate specific cognitive changes, neuropsychiatric symptoms (NPS), and personality traits that may act as early indicators of AD in family members compared to controls.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!